IN2012DN00763A - - Google Patents

Download PDF

Info

Publication number: IN2012DN00763A
Authority: IN; India
Prior art keywords: diseases; hdl; prophylaxis; atherosclerosis; medicaments
Prior art date: 2009-09-11

Application number

Other languages

English (en)

Inventor

Stephan Roever

Matthew Wright

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-11

Filing date

2010-09-08

Publication date

2015-06-26

2010-09-08 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2015-06-26 Publication of IN2012DN00763A publication Critical patent/IN2012DN00763A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN763DEN2012 2009-09-11 2010-09-08 IN2012DN00763A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09170097		2009-09-11
PCT/EP2010/063136 WO2011029827A1 (fr)	2009-09-11	2010-09-08	5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl

Publications (1)

Publication Number	Publication Date
IN2012DN00763A true IN2012DN00763A (fr)	2015-06-26

Family

ID=42830122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN763DEN2012 IN2012DN00763A (fr)	2009-09-11	2010-09-08

Country Status (35)

Country	Link
US (1)	US8227491B2 (fr)
EP (1)	EP2475645B1 (fr)
JP (1)	JP5604520B2 (fr)
KR (1)	KR101382871B1 (fr)
CN (1)	CN102639506B (fr)
AR (2)	AR078352A1 (fr)
AU (1)	AU2010294277B2 (fr)
BR (1)	BR112012005511B8 (fr)
CA (1)	CA2771493C (fr)
CL (1)	CL2012000611A1 (fr)
CO (1)	CO6491033A2 (fr)
CR (1)	CR20120089A (fr)
CY (1)	CY1114377T1 (fr)
DK (1)	DK2475645T3 (fr)
EC (1)	ECSP12011723A (fr)
ES (1)	ES2423821T3 (fr)
HK (1)	HK1172021A1 (fr)
HR (1)	HRP20130869T1 (fr)
IL (1)	IL217920A (fr)
IN (1)	IN2012DN00763A (fr)
MA (1)	MA33563B1 (fr)
MX (1)	MX2012002254A (fr)
MY (1)	MY161103A (fr)
NZ (1)	NZ597514A (fr)
PE (1)	PE20120863A1 (fr)
PL (1)	PL2475645T3 (fr)
PT (1)	PT2475645E (fr)
RS (1)	RS52987B (fr)
RU (1)	RU2541475C2 (fr)
SG (1)	SG179035A1 (fr)
SI (1)	SI2475645T1 (fr)
TW (1)	TWI412363B (fr)
UA (1)	UA107088C2 (fr)
WO (1)	WO2011029827A1 (fr)
ZA (1)	ZA201201599B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012031817A1 (fr)	2010-09-09	2012-03-15	F. Hoffmann-La Roche Ag	Détermination des niveaux de protéine abca1 dans des cellules
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) *	2010-10-22	2012-04-26	Pascal Dott	Process for the preparation of nicotinamide derivatives
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (fr) *	2013-05-06	2014-11-13	F. Hoffmann-La Roche Ag	Procédés d'identification de modulateurs d'osbpl7 et utilisation de ces modulateurs pour traiter les maladies associées à osbpl7
US20200085810A1 (en)	2018-07-26	2020-03-19	Hoffmann-La Roche Inc.	Compounds for use in treating kidney disorders
US11814354B2 (en)	2021-09-08	2023-11-14	River 3 Renal Corp.	Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI259180B (en) *	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
PL1868999T3 (pl) *	2005-04-06	2009-12-31	Hoffmann La Roche	Pochodne pirydyno-3-karboksyamidu jako odwrotni agoniści CB1
AU2007304365A1 (en) *	2006-10-04	2008-04-10	F. Hoffmann-La Roche Ag	3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents

2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/fr active Active
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/fr active Application Filing
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 CA CA2771493A patent/CA2771493C/fr active Active
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active Active
- 2010-09-08 RS RS20130395A patent/RS52987B/en unknown
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
- 2012-12-12 HK HK12112824.3A patent/HK1172021A1/xx unknown
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
- 2013-09-16 HR HRP20130869AT patent/HRP20130869T1/hr unknown
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es unknown

Also Published As

Publication number	Publication date
TW201114427A (en)	2011-05-01
CO6491033A2 (es)	2012-07-31
SI2475645T1 (sl)	2013-10-30
CN102639506B (zh)	2014-09-03
AR114032A2 (es)	2020-07-15
IL217920A (en)	2015-11-30
ECSP12011723A (es)	2012-04-30
HRP20130869T1 (hr)	2013-10-25
SG179035A1 (en)	2012-04-27
MY161103A (en)	2017-04-14
CN102639506A (zh)	2012-08-15
UA107088C2 (xx)	2014-11-25
ES2423821T3 (es)	2013-09-24
EP2475645B1 (fr)	2013-07-03
KR101382871B1 (ko)	2014-04-08
CA2771493C (fr)	2017-08-29
NZ597514A (en)	2013-10-25
RS52987B (en)	2014-02-28
US20110065759A1 (en)	2011-03-17
IL217920A0 (en)	2012-03-29
AU2010294277A1 (en)	2012-02-09
HK1172021A1 (en)	2013-04-12
TWI412363B (zh)	2013-10-21
CR20120089A (es)	2012-03-22
PL2475645T3 (pl)	2013-12-31
RU2541475C2 (ru)	2015-02-20
AU2010294277B2 (en)	2015-07-09
KR20120048040A (ko)	2012-05-14
MA33563B1 (fr)	2012-09-01
CL2012000611A1 (es)	2012-09-07
JP2013504534A (ja)	2013-02-07
WO2011029827A1 (fr)	2011-03-17
BR112012005511A2 (pt)	2016-04-19
PE20120863A1 (es)	2012-07-23
BR112012005511B8 (pt)	2021-05-25
US8227491B2 (en)	2012-07-24
RU2012113924A (ru)	2013-10-20
CY1114377T1 (el)	2016-08-31
CA2771493A1 (fr)	2011-03-17
JP5604520B2 (ja)	2014-10-08
MX2012002254A (es)	2012-03-16
DK2475645T3 (da)	2013-07-22
PT2475645E (pt)	2013-08-05
AR078352A1 (es)	2011-11-02
EP2475645A1 (fr)	2012-07-18
BR112012005511B1 (pt)	2021-03-02
ZA201201599B (en)	2012-11-28

Publication	Publication Date	Title
MX2013002660A (es)	2013-04-09	Heteroarilmetilamidas.
PH12019502355A1 (en)	2021-07-05	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX2013004759A (es)	2013-07-03	Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
IN2015DN01156A (fr)	2015-06-26
IN2012DN01233A (fr)	2015-05-15
MX338712B (es)	2016-04-28	Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
MD20140002A2 (ro)	2014-06-30	Indazoli
WO2014028600A3 (fr)	2014-04-24	Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
TN2012000549A1 (en)	2014-04-01	Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
TN2012000428A1 (en)	2014-01-30	Bisaryl-bonded aryltriazolones and use thereof
IN2014DN09434A (fr)	2015-07-17
TN2011000370A1 (en)	2013-03-27	Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX344238B (es)	2016-12-07	Compuestos de tetrazol y métodos para preparar y usar los mismos.
IN2012DN02081A (fr)	2015-08-21
PH12014501967A1 (en)	2014-11-17	Benzodioxanes in combination with other actives for inhibiting leukotriene production
IN2012DN00971A (fr)	2015-04-10
GB2511685A (en)	2014-09-10	Muscarinic m1 receptor agonists
MX2013011691A (es)	2014-05-27	Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
GEP20186880B (en)	2018-07-25	2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12013500007A1 (en)	2017-05-19	Piperidine derivatives and their use for the treatment of metabolic disorders
MY157429A (en)	2016-06-15	Trpm8 antagonists and their use in treatments
IN2012DN00763A (fr)	2015-06-26
MY167898A (en)	2018-09-26	Co-crystals and salts of ccr3-inhibitors
MD20140044A2 (ro)	2014-08-31	2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
MX342947B (es)	2016-10-18	Tratamiento de diabetes tipo 2.